[go: up one dir, main page]

MX2022014577A - Gel intestinal de levodopa y carbidopa y metodos de uso. - Google Patents

Gel intestinal de levodopa y carbidopa y metodos de uso.

Info

Publication number
MX2022014577A
MX2022014577A MX2022014577A MX2022014577A MX2022014577A MX 2022014577 A MX2022014577 A MX 2022014577A MX 2022014577 A MX2022014577 A MX 2022014577A MX 2022014577 A MX2022014577 A MX 2022014577A MX 2022014577 A MX2022014577 A MX 2022014577A
Authority
MX
Mexico
Prior art keywords
methods
levodopa
intestinal gel
carbidopa
carbidopa intestinal
Prior art date
Application number
MX2022014577A
Other languages
English (en)
Inventor
John M Lipari
Ye Huang
Alexandru Deac
Alexander RUGGLES
Thin Yu Tun
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2022014577A publication Critical patent/MX2022014577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación proporciona (a) una composición farmacéutica que comprende un agente activo de levodopa y un agente activo de carbidopa y (b) métodos para tratar la enfermedad de Parkinson y afecciones asociadas que comprenden administrar la composición farmacéutica a un sujeto con enfermedad de Parkinson.
MX2022014577A 2016-07-20 2019-01-18 Gel intestinal de levodopa y carbidopa y metodos de uso. MX2022014577A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662364770P 2016-07-20 2016-07-20

Publications (1)

Publication Number Publication Date
MX2022014577A true MX2022014577A (es) 2023-01-11

Family

ID=59506369

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019000849A MX2019000849A (es) 2016-07-20 2017-07-20 Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2022014577A MX2022014577A (es) 2016-07-20 2019-01-18 Gel intestinal de levodopa y carbidopa y metodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019000849A MX2019000849A (es) 2016-07-20 2017-07-20 Gel intestinal de levodopa y carbidopa y metodos de uso.

Country Status (9)

Country Link
US (3) US20180021280A1 (es)
EP (1) EP3487479A1 (es)
JP (3) JP2019523249A (es)
CN (1) CN109715139A (es)
AU (2) AU2017299710A1 (es)
BR (1) BR112019001082A2 (es)
CA (1) CA3031254A1 (es)
MX (2) MX2019000849A (es)
WO (1) WO2018017850A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
MA52122A (fr) 2018-03-02 2021-04-28 Chiesi Farm Spa Formulation pharmaceutique pour administration intraduodénale comprenant de la mélévodopa et de la carbidopa
EP4023292A4 (en) * 2019-08-30 2023-09-06 TERUMO Kabushiki Kaisha INJECTION FORMULATION
EP4616878A1 (en) * 2024-03-15 2025-09-17 Cosmo Technologies Ltd. Cannula for rectal administration of an enema and compositions for use therewith

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
CN1901881A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 用于增强的吸收的组合物和剂型
CN101636145B (zh) * 2006-05-31 2014-04-23 雅培产品有限公司 长期24小时经肠给予左旋多巴/卡比多巴
DE102006034346B4 (de) * 2006-07-25 2008-11-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zum periodischen Messen der Fließgrenze von Dispersionen sowie deren Verwendung
US10130755B2 (en) * 2013-12-31 2018-11-20 Abbvie Inc. Devices and methods for delivering a beneficial agent to a user
CN107072973A (zh) * 2014-09-04 2017-08-18 劳波索尔制药有限公司 含左旋多巴、多巴胺脱羧酶抑制剂和comt抑制剂的药物组合物及其施用方法
SE538425C2 (en) * 2014-09-04 2016-06-21 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Also Published As

Publication number Publication date
AU2017299710A1 (en) 2019-01-31
JP2025000924A (ja) 2025-01-07
WO2018017850A1 (en) 2018-01-25
JP2019523249A (ja) 2019-08-22
US20180021280A1 (en) 2018-01-25
CN109715139A (zh) 2019-05-03
US20230129413A1 (en) 2023-04-27
BR112019001082A2 (pt) 2019-04-30
JP2022166217A (ja) 2022-11-01
MX2019000849A (es) 2019-09-13
AU2023203340A1 (en) 2023-06-22
CA3031254A1 (en) 2018-01-25
US20210059968A1 (en) 2021-03-04
EP3487479A1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
MX2024001203A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con moduladores metabolicos para usarse en tratar enfermedades del higado graso.
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
CU20200012A7 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112017023170A2 (pt) dispositivo de banho medicinal e seu uso
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
AR106313A1 (es) Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
AR103448A1 (es) Gel intestinal de levodopa y carbidopa y métodos de uso
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
HK1245638A1 (en) Levodopa and carbidopa intestinal gel and methods of use
AR130700A2 (es) Composiciones de grapiprant y métodos para su utilización
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización